Empawish-M-12.5/500

Empawish-M-12.5/500 (Empagliflozin 12.5 mg + Metformin HCl 500 mg) tablet is an advanced combination therapy for the effective management of type 2 diabetes mellitus. It combines empagliflozin, an SGLT2 inhibitor, with metformin, a widely trusted first-line anti-diabetic agent, to provide reliable and sustained blood sugar control. By working through two complementary mechanisms, this combination helps reduce excess glucose levels, improve insulin sensitivity, and support overall metabolic balance. It is commonly prescribed for adults with type 2 diabetes, particularly when monotherapy does not provide adequate control.

How Does Empawish-M-12.5/500 Work?

This combination manages blood glucose through two distinct pathways:

Empagliflozin (12.5 mg):
It works on the kidneys by blocking the SGLT2 protein, reducing glucose reabsorption, and supporting its excretion through urine. This helps lower blood sugar levels independently of insulin and may also contribute to mild weight loss and blood pressure reduction.

Metformin (500 mg):
Works by reducing glucose production in the liver and improving the body’s sensitivity to insulin and helps in better utilization of glucose by peripheral tissues.

The combination provides a comprehensive approach to managing hyperglycemia by targeting both the kidneys (removing glucose) and the pancreas (improving insulin response). It offers improved glycemic control, potential weight loss, and low risk of hypoglycemia when used without other insulin-stimulating drugs.

Clinical Benefits 

The combination offers greater reduction in HbA1c (long-term blood sugar) and fasting plasma glucose compared to either drug alone.

Empagliflozin is known to reduce the risk of cardiovascular death in adults with T2DM and established cardiovascular disease. It also helps protect kidneys by slowing the decline of kidney function in diabetic patients.

Empagliflozin aids in modest weight reduction by helping the body excrete excess glucose through urine.

When used alone or with other non-insulin medications, this combination has a low risk of causing dangerously low blood sugar.

A single tablet containing both medications improves adherence compared to taking separate pills (pill burden reduction).

Empagliflozin removes glucose via urine, while linagliptin increases insulin secretion and suppresses glucagon production, targeting multiple pathways.

Dosage & Administration

To be taken as directed by the physician.
Usually recommended once daily with meals to minimize gastrointestinal discomfort.

Disclaimer

Results may vary from patient to patient. This product does not cure diabetes but helps in its effective management when used as prescribed. Please consult your healthcare provider for proper diagnosis and treatment.